TY - JOUR
T1 - Pharmacological approaches to the management of schizophrenia: 10 years on
AU - Castle, David Jonathan
AU - Keks, Nicholas Alexander
AU - Newton, Richard
AU - Schweitzer, Isaac
AU - Copolov, David Leon
AU - Paoletti, Nick
AU - Burrows, Graham D
AU - John, Tiller W G
PY - 2013
Y1 - 2013
N2 - OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia.
METHOD: Selective literature review.
RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required.
CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.
AB - OBJECTIVE: To review the contemporary landscape regarding pharmacological treatments for schizophrenia.
METHOD: Selective literature review.
RESULTS: Newer antipsychotic agents include aripiprazole, asenapine, paliperidone, sertindole and ziprasidone. Each has some particular benefits and some shortcomings. Overall treatment efficacy (for positive symptoms at least) has not advanced substantially but some newer agents might have a better profile than older typical agents for negative and cognitive symptoms. Metabolic side effects and hyperprolactinaemia remain a problem with some of the newer agents and appropriate monitoring is required.
CONCLUSIONS: Whilst newer antipsychotics have been welcome additions to our pharmacological armamentarium, mostly in terms of tolerability, we have still not seen a quantum leap agent brought to market. Mechanisms of action apart from post-synaptic dopamine blockade appear worthy of further investigation in this regard.
UR - http://apy.sagepub.com/content/21/4/329.full.pdf
U2 - 10.1177/1039856213486211
DO - 10.1177/1039856213486211
M3 - Article
SN - 1039-8562
VL - 21
SP - 329
EP - 334
JO - Australasian Psychiatry
JF - Australasian Psychiatry
IS - 4
ER -